

INSTITUTIONAL BIOSAFETY COMMITTEE

**Tuesday, 06/16/2026 12:03 PM
MSBII 5A116**

Chairperson

Mingtao Zeng, PhD

Board Members

Anthony W Baird, DSc
Jeana E. Barrow, DVM
Huanyu Dou, MD
Pallavi Dubey, PhD
Ivan E Flores, BS
Daniel Gonzales, BA

Administrative Staff

Amanda Ortiz
Myrna Arvizo

MEMBERS PRESENT
Anthony W Baird, DSc, Jeana E. Barrow, DVM, Huanyu Dou, MD, Ivan E Flores, BS, Mingtao Zeng, PhD
MEMBERS ABSENT
Daniel Paul Gonzales, BMS
STAFF PRESENT
Myrna Arvizo, BMS, CIP, CHRC, Amanda Diazdeleon, Mireya Kosonoy
GUESTS PRESENT

CALL TO ORDER

Mingtao Zeng, PhD called the meeting to order at 12:03 p.m. Quorum is 5 members. 5 members are present at the call to order, including scientific, non-scientific and non-affiliated members. 5 members present at conclusion.

All proceedings and discussion in the upcoming meeting are confidential and should not be discussed outside of the meeting. Additionally, any member who has a conflict of interest that would preclude making an objective determination about a study should recuse him/herself from voting on the study.

A draft of the meeting minutes from 05/19/2026 was distributed for review on 05/22/2026. There were no controversial entries or objections. A motion to approve the meeting minutes as written was made by AB and seconded by JB. The committee voted unanimously to approve the minutes.

The meeting was adjourned at 12:35 p.m.

MISCELLANEOUS

Review of [OP 73.04](#), Research Involving Controlled Substances and Laboratory Apparatus, and its attachments. These were also reviewed at the June IACUC meeting. This is a reminder about the documentation required for the use of controlled substances. The IACUC will be reviewing these documents at the semi-annual inspections. In instances where the controlled substances are not associated to an animal protocol, Safety Services will be inspecting the documents during their quarterly inspections.

Review of [OP 73.12](#), Possession and Use of Health and Human Services (HHS) Listed Toxins in Permissible Amounts, and its attachments. This is a reminder about the required documentation that is needed for PIs who have select agents. The OP indicates that a PI must maintain specific documentation, including completion of a self-inspection list, and that there will be periodic announced and unannounced laboratory inspections by Safety Services.

[OP 73.12a](#)

[OP 73.12b](#)

[OP 73.12c](#)

[OP 73.12d](#)

Dr. Dubey is no longer with the IBC as of 6/16/2026.

3-YEAR RENEWALS

N/A

AMENDMENTS

IBC# 25002

Full Renewal Expiration Date: 12/31/2027

Murali Bagalur Muniraju, Ph.D./TTUHSC El Paso - SOM - Molecular and Translational Medicine

Biosafety Level: BSL 2

ADMINISTRATIVE COMMENT:

The PI is requesting the following changes.

1. Adds replication-incompetent lentiviral vectors for BSL-2 mammalian cell studies involving CRISPR/Cas9 gene knockout and/or recombinant protein expression.
2. Remove names: Janet Olivas | Gokul Sudhakaran | Jazmine Ramirez | Mahek Mirza

MEMBER COMMENTS:

Comment:

PI is seeking to 1. add replication-incompetent lentiviral vectors for BSL-2 mammalian cell studies involving CRISPR/Cas9 gene knockout and/or recombinant protein expression; and,

2. Remove the following names from the study : Janet Olivas | Gokul Sudhakaran | Jazmine Ramirez | Mahek Mirza

Section 8 has an added section on recombinant DNA methodology. Utilizing a BSL-2 room, the study includes plasmid vectors. with synthetic nucleopeptides for PCR duplication. Standard antibiotic resistance genes are present. The plasmid vectors pose minimal risk, and the Herpes Virus does not further increase study risk.

Section 9. as written is concise and addresses risk assessment, safety procedures and appropriate disposal processes. Intra TTHSCEP, and external training is specified, as is transportation and handling of study materials.

Section 10. study as written does not involve, or never will involve, genetic sequencing of human DNA, or use

software to analyze human genetic sequencing data.

Comment:

All safety concerns addressed very well in this protocol. Safety and BSO have no concerns with this protocol.

RECOMMENDATIONS: Approve

MOTION AND VOTE: The TTUHSC EP Institutional Biosafety Committee (IBC) reviewed this protocol at their full board meeting and granted unrestricted approval.

Total Members Voting: **5** [For: **5** Absent: **0** Against: **0** Conflict of Interest: **0** Not Present: **0** Abstained: **0**]

SUBMISSION OUTCOME: Approved

IBC# 21009

Full Renewal Expiration Date: 03/31/2027

Ramadevi Subramani Reddy, PhD/TTUHSC El Paso - SOM - Molecular and Translational Medicine

Biosafety Level: BSL 2

ADMINISTRATIVE COMMENT:

MEMBER COMMENTS:

Comment:

The PI is requesting to add human leukemia cell lines. In the Submission Components tab, use the "Compare to Last Approved" feature to review the changes made to the study application. Green highlights indicate additions, and pink highlights indicate removed content.

MEMBER COMMENTS:

Comment:

No comments or concerns.

Comment:

Assessing the therapeutic efficacy of anti-cancer drugs. Research proposal focuses on cancer biology specifically in the field of drug discovery, prevention and treatment of cancers. Currently, therapeutic efficacy of bioactive molecules on different cancer types is being assessed. The molecular mechanisms involved in cancer progression, metastasis and treatment are being studied. In parallel, the role of growth factors, hormones and their receptors on cancer growth and metastasis is also being evaluated. Understanding the mechanisms involved in cancer progression and metastasis will be of significance in designing innovative strategies for prevention and treatment of cancer. Previously approved study with modifications as follows: adding human leukemia Cell lines: KASUMI-1, HL-60, THP-1, K-562r, MOLT4, PCS-800-012, PCS-800-011, and PBMCs are requested to be added to the study.

Comment:

No safety concerns with this protocol from Safety Services or Biological Safety Officer.

RECOMMENDATIONS: Approve

MOTION AND VOTE: Total Members Voting: **5**

[For: **5** Absent: **0** Against: **0** Conflict of Interest: **0** Not Present: **0** Abstained: **0**]

SUBMISSION OUTCOME: Approved

IBC# 26005

Full Renewal Expiration Date: 01/31/2029

Raja Veerapandian/TTUHSC El Paso - SOM - Molecular and Translational Medicine

Biosafety Level: BSL 2

ADMINISTRATIVE COMMENT:

Comment:

The PI is requesting the following changes.

1. Sheryl Rodriguez- Added for shipping hazardous materials and also for shipping biological materials inside campus

2. Microbial strains and cell lines can also be purchased through any approved commercial vendors through Techbuy.
3. Added Salmonella Typhimurium, Klebsiella pneumoniae, Pseudomonas aeruginosa and Escherichia coli for checking the non-specific activity of therapeutics evaluated in our lab.
4. Candida albicans grace or Double Barcoded (DBC) strain library will be procured from Leah Cowen laboratory at the University of Toronto after the execution of a fully executed MTA with Merck Sharp & Dohme Corp.
5. HSC-2, HO-1-N-1 and Macrophage Cell Line Derived from Wild Type Mice was added in cell lines column.
6. Human saliva (pooled) can also be purchased through commercial vendors via techbuy, for example it is available in <https://www.medixbiochemica.com/saliva-pooled-hu-991-05-p>.
7. Extra Vectors added: pHA280, pMiniT2.0 vector, pmal-c6tpet series vectors like 15, 30, 28-mbp-TEV, 21mbpx-spycatcher, pUC19-Q73QW6, pYUB1471, pYUB1363, p0004-sacB, pCHERRY3 and 10, PJL 31, 32, 33, 34, pEGFP-N3, pIB plasmids (166, 184km, 184em, 163, 164, 165, 167, 168, 169, 170, 185, 190), pKM series plasmids- pKM512, pKM493, pKM496, pKM495, pKM492-Myc-His, pKM491-Flag-His, pKM490-Clip, pKM489-Snap, pKM468-EGFP, pKM464, pKM446, pKM461, pKM444, lentiCRISPR v2; pRS118; pENO1-iRFP-NATr. These plasmids can be used for cloning genes or generating fluorescent strains or mutants.
8. Escherichia coli (NEB® 5-alpha, NEB® 10-beta, Lemo21 DE3, NEB turbo, NEB stable, NEB® 5-alpha, SHuffle, NEBExpress, T7 Express, Rosetta(DE3)).
9. Safety aspects for Salmonella Typhimurium; Klebsiella pneumoniae; Pseudomonas aeruginosa; Escherichia coli strains were added.
10. Section 10 - H.B. 130 Texas Genomic Act Compliance: In future we will be doing RNA -seq from BCG infected human cell lines or pooled human PBMCs

MEMBER COMMENTS:**Comment:**

The PI has adequately addressed all biosafety issues in the amendment. No concerns.

Comment:

Information in this protocol is very thorough and detailed. Sections 9.3-Special Constraints and 9.4-precautions for personnel are addressed with great information. Safety and BSO have no need for additional information.

Comment:

No comments or concerns.

RECOMMENDATIONS: Approve

MOTION AND VOTE: The TTUHSC EP Institutional Biosafety Committee (IBC) reviewed this protocol at their full board meeting and granted unrestricted approval.

Total Members Voting: **5** [For: **5** Absent: **0** Against: **0** Conflict of Interest: **0** Not Present: **0** Abstained: **0**]

SUBMISSION OUTCOME: Approved

INITIAL REVIEWS

IBC# 26010

Full Renewal Expiration Date: 06/30/2029

Alex Gonzalez DDS/TTUHSC El Paso - SOD - School of Dentistry

Biosafety Level: BSL 2

ADMINISTRATIVE COMMENT:**Comment:**

The PI has responded to the concerns of the reviewers.

MEMBER COMMENTS:**Comment:**

Summary: The investigators have responded to all six stipulations. Five stipulations have been

addressed, and one stipulation (human subject risk statement) has been reasonably clarified.

Stipulation 1: Study Design Consistency

The investigators state that protocol inconsistencies regarding study design, recruitment methods, and the number of teeth were addressed. The response appears satisfactory.

Stipulation 2: Transport of Extracted Teeth

Additional information regarding the movement of extracted teeth between campus locations was reportedly added. Recommendation: Confirm that transport procedures include appropriate labeling, containment, and handling measures consistent with institutional biosafety requirements.

Stipulation 3: Classification of Human Blood

Investigators revised the protocol to exclude human blood from the study. This response adequately addresses the concern.

Stipulation 4: Biosafety Procedures

Investigators indicate that aerosol hazards, sharps hazards, contamination risks, and mitigation procedures were added to the protocol. Response appears adequate pending confirmation that PPE requirements, decontamination procedures, and sharps disposal methods are clearly described.

Stipulation 5: Human Subject Risk Statement

Investigators did not accept the stipulation and clarified that root canal procedures will be performed in vitro on extracted teeth and not on living patients. This clarification appears reasonable, provided the revised protocol consistently reflects an in vitro design and no clinical procedures are performed on human subjects.

Stipulation 6: PHI/Data Confidentiality

Investigators amended the protocol to state that no PHI, demographics, or medical history information will be collected. The discrepancy identified in the original submission appears to have been resolved.

Comment:

No Safety or BSO concerns.

RECOMMENDATIONS: Approve

MOTION AND VOTE: The TTUHSC EP Institutional Biosafety Committee (IBC) reviewed this protocol at their full board meeting and granted unrestricted approval.

Total Members Voting: **5** [For: **5** Absent: **0** Against: **0** Conflict of Interest: **0** Not Present: **0** Abstained: **0**]

SUBMISSION OUTCOME: Approved

EXPEDITED REVIEW

N/A

ADMINISTRATIVE-ANNUAL STATUS REPORTS

N/A

ADMINISTRATIVE-AMENDMENTS

IBC# 25008

Full Renewal Expiration Date: 09/30/2028

Darby Carmelle Ghislaine Mayer/TTUHSC El Paso - SOM - Medical Education

Biosafety Level: BSL 2

ADMINISTRATIVE COMMENT:

Comment:

Personnel change to add Abhisha Khadka. COI, FD, and LSE are complete. This protocol does not involve recombinant or synthetic nucleic acid molecules.

RECOMMENDATIONS: Acknowledged

SUBMISSION OUTCOME: Administratively Acknowledged

IBC# 25008

Full Renewal Expiration Date: 09/30/2028

Darly Carmelle Ghislaine Mayer/TTUHSC El Paso - SOM - Medical Education

Biosafety Level: BSL 2

ADMINISTRATIVE COMMENT:

Comment:

Personnel change to add Tyler Lee. COI, FD, and LSE are complete. This protocol does not involve recombinant or synthetic nucleic acid molecules.

RECOMMENDATIONS: Acknowledged

SUBMISSION OUTCOME: Administratively Acknowledged

IBC# 10010

Full Renewal Expiration Date: 07/31/2028

Mingtao Zeng, PhD/TTUHSC El Paso - SOM - MTM-CoE in Infectious Diseases

Biosafety Level: BSL 2+

ADMINISTRATIVE COMMENT:

Comment:

Personnel change to remove Alejandra Munoz, Briana Olivares, Maryam Amin, and Jorge Ortiz. Application 1.11 has been revised.

RECOMMENDATIONS: Acknowledged

SUBMISSION OUTCOME: Administratively Acknowledged

IBC# 24005

Full Renewal Expiration Date: 04/30/2027

Dale W Quest, Ph.D., RN(NP)/TTUHSC El Paso - SOM - Medical Education

Biosafety Level: BSL 2

ADMINISTRATIVE COMMENT:

Comment:

Personnel change to add Marah Hamdan. COI, FD, and LSE are complete. This protocol does not involve recombinant or synthetic nucleic acid molecules.

RECOMMENDATIONS: Acknowledged

SUBMISSION OUTCOME: Administratively Acknowledged

IBC# 14005

Full Renewal Expiration Date: 05/31/2029

Munmun Chattopadhyay, PhD/TTUHSC El Paso - SOM - MTM-CoE in Diabetes and Metabolism

Biosafety Level: BSL 2

ADMINISTRATIVE COMMENT:

Comment:

The PI is submitting a revised application to add questions required by Texas House Bill 130. The answer to the question was no. There are no other changes. A new license will not be issued.

RECOMMENDATIONS: Acknowledged

SUBMISSION OUTCOME: Administratively Acknowledged

IBC# 22010

Full Renewal Expiration Date: 08/31/2028

Umadevi Kandalam, PhD/TTUHSC El Paso - SOD - School of Dentistry

Biosafety Level: BSL 2

ADMINISTRATIVE COMMENT:

Comment:

Personnel change to add Sara Hanbali. COI, FD, and LSE are complete. This protocol does not involve recombinant or synthetic nucleic acid molecules.

RECOMMENDATIONS: Acknowledged

SUBMISSION OUTCOME: Administratively Acknowledged

TERMINATIONS

N/A

BSO REPORT

N/A